Vertex Pharmaceuticals Incorporated (VRTX)
VRTXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$549.18
-1.69 (-0.31%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $551.95 +0.20%
- Market cap
- $139.94bn
- P/E
- 32.3
- EPS, last 4 quarters
- $17.01
- Dividend yield
- –
- Day range
- –
- 52-week range
- $410.50 to $568.67
- Average volume
- 1.28m
- Previous close
- $550.87
Analysts
22 coveringBuy20 buy, 2 hold, 0 sell
Targets a year out average $616.37, +12.2% from here
Earnings
next estimate $3.56Next report
Dec 2025
+5.7%
Mar 2026
+7.0%
Jun 2026
+1.2%
Sep 2026
-3.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $3.19bn | $2.99bn | $3.33bn | $3.44bn |
| Gross profit | $2.72bn | $2.59bn | $2.84bn | $2.91bn |
| Operating income | $1.21bn | $1.14bn | $1.25bn | $712.90m |
| Net income | $1.19bn | $1.03bn | $1.10bn | $653.60m |
Last four quarters: revenue $12.95bn, margin 30.7%, free cash flow $3.20bn
News
8 latest- The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationThe Motley Fool · 1 day ago
- Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?The Motley Fool · 3 days ago
- XLV, ISRG, DHR, VRTX: ETF Inflow AlertBNK Invest · 4 days ago
- Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 YearsThe Motley Fool · 5 days ago
- Vertex Q3 Earnings Call Highlights Revenue Beat and Pipeline ExpansionZacks · 7 days ago
- CRSP's Q3 Loss Wider Than Expected, Sales Beat EstimatesZacks · 7 days ago
- VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedZacks · 7 days ago
- Vertex: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Nov 3, 2026
The company
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain and acromegaly, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- vrtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.